Selank
CognitiveAnxiolytic tuftsin analog / researchExperimental
Synthetic tuftsin analog developed in Russia as an anxiolytic peptide (often nasal). Not FDA-approved.
For research use only.
Key Facts
- CAS
- 129954-34-3
- Molecular Weight (MW)
- ≈751.9 g/mol
- Half-life
- Not established (varies by route; nasal studied in RU)
- Unit
- mcg
- Administration Route
- Intranasal or parenteral in research settings
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- GABAergic systemsEnkephalin metabolism
Overview
Synthetic tuftsin analog developed in Russia as an anxiolytic peptide (often nasal). Not FDA-approved.
Protocol
- Dosage Range
- Not established for FDA-approved use
- Frequency
- —
- Cycle
- —
- Administration Route
- Intranasal or parenteral in research settings
- Reconstitution Guide
- —
Science
Mechanism of Action
Modulates GABA and monoamine systems and enkephalin degradation in animal and small human studies; immune-modulating tuftsin ancestry.
Targets
GABAergic systemsEnkephalin metabolism
Studies
- Selank anxiolytic peptide— Journal/year not available
Benefits
Anxiety/nootropic research literature
Potential Side Effects
- Nasal irritation (intranasal)
- Fatigue
References
- PMID 18454096External link · Year —